Artivion, Inc. (NYSE:AORT) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• Artivion, Inc. (NYSE:AORT) has received a consensus rating of "Buy" from seven brokerages, with one analyst granting a "strong buy" recommendation and an average price target of $39.80.
• The company reported a quarterly EPS of $0.24, surpassing analyst expectations of $0.11, and achieved revenue growth of 15.3% year-over-year, totaling $112.97 million.
• Recent insider selling included significant transactions from executives, with SVP Jean F. Holloway selling shares valued at over $1 million, reflecting a decrease in ownership by 11.95%.

Artivion, Inc. (NYSE:AORT - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $39.80.

A number of research analysts have recently weighed in on AORT shares. LADENBURG THALM/SH SH cut Artivion from a "buy" rating to a "neutral" rating and lifted their price objective for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Wall Street Zen cut Artivion from a "buy" rating to a "hold" rating in a report on Sunday. Canaccord Genuity Group boosted their price target on Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, Oppenheimer reissued an "outperform" rating on shares of Artivion in a report on Friday, August 8th.

Artivion Stock Performance

Shares of AORT stock traded down $0.87 during trading hours on Friday, reaching $41.98. 157,253 shares of the company traded hands, compared to its average volume of 442,568. Artivion has a 12-month low of $21.97 and a 12-month high of $43.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The company has a market cap of $1.98 billion, a P/E ratio of -99.95 and a beta of 1.64. The firm has a 50-day moving average price of $32.50 and a 200 day moving average price of $28.50.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $112.97 million for the quarter, compared to analysts' expectations of $107.96 million. The firm's revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Artivion will post 0.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Jean F. Holloway sold 23,356 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $43.01, for a total value of $1,004,541.56. Following the transaction, the senior vice president directly owned 172,129 shares of the company's stock, valued at approximately $7,403,268.29. The trade was a 11.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John E. Davis sold 10,802 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total value of $471,723.34. Following the sale, the insider directly owned 208,778 shares in the company, valued at $9,117,335.26. This trade represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 96,564 shares of company stock valued at $3,277,527 in the last 90 days. 8.10% of the stock is currently owned by company insiders.

Institutional Trading of Artivion

Hedge funds have recently modified their holdings of the company. Legacy Advisors LLC purchased a new stake in shares of Artivion during the 1st quarter worth approximately $28,000. MCF Advisors LLC raised its holdings in shares of Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after acquiring an additional 614 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after acquiring an additional 538 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Artivion during the 4th quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Artivion by 447.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company's stock worth $168,000 after acquiring an additional 4,422 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.